---
title: "ADC Therapeutics SA | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 19.25 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295805857.md"
datetime: "2026-08-13T13:18:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295805857.md)
  - [en](https://longbridge.com/en/news/295805857.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295805857.md)
generator: "portal-rs"
---

# ADC Therapeutics SA | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 19.25 M

Revenue: As of FY2026 Q2, the actual value is USD 19.25 M, beating the estimate of USD 18.9 M.

EPS: As of FY2026 Q2, the actual value is USD -0.11.

EBIT: As of FY2026 Q2, the actual value is USD -4.876 M.

#### Absence of Historical Financial Data

The provided reference documents, including a FORM 8-K filing and a corporate presentation, do not contain actual historical financial results, operational metrics, segment revenues, cash flow, or unique historical metrics. Specifically, no historical financial metrics such as net income, gross margin, operating profit, operating margin, operating costs, operating cash flow, or free cash flow, including Year-over-Year comparisons, are provided. 

#### Unique Metrics

ADC Therapeutics SA highlights a potential multi-billion-dollar US market opportunity across 2L+ DLBCL and 2L+ indolent lymphomas. The 2L+ DLBCL market alone is projected to be approximately $3 billion in the U.S. by 2030. 

#### Outlook / Guidance

ADC Therapeutics SA anticipates revenue growth in 2027 and aims to sustain or increase ZYNLONTA® revenue in the future. The company expects its cash runway to extend into at least 2028, based on maintaining the minimum liquidity required by its loan agreement covenants. Additionally, ADC Therapeutics SA is evaluating regulatory pathways for ZYNLONTA to achieve full approval and expand into earlier lines of DLBCL therapy, with further updates on regulatory strategy and timing planned for the future.

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA](https://longbridge.com/en/news/295792223.md)
- [ADC Therapeutics posts corporate presentation highlighting Zynlonta growth opportunity in B-cell lymphomas](https://longbridge.com/en/news/295800995.md)
- [ADC Therapeutics Q2 loss narrows; cuts 17% workforce](https://longbridge.com/en/news/295791965.md)
- [ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss](https://longbridge.com/en/news/295792525.md)
- [ADC Therapeutics (ADCT) to Release Earnings on Tuesday](https://longbridge.com/en/news/277966267.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**